Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

ClinicalTrials.gov ID: NCT04862286

Public ClinicalTrials.gov record NCT04862286. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 3:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)

Study identification

NCT ID
NCT04862286
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
132 participants

Conditions and interventions

Conditions

Interventions

  • Risankizumab Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 23, 2021
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028
Last update posted
Aug 11, 2025

2021 – 2028

United States locations

U.S. sites
15
U.S. states
9
U.S. cities
15
Facility City State ZIP Site status
UAB Department of Dermatology /ID# 252305 Birmingham Alabama 35233
First OC Dermatology /ID# 226942 Fountain Valley California 92708
Integrative Skin Science and Research /ID# 226108 Sacramento California 95815
University of California San Diego - Rady Children's Hospital San Diego /ID# 252348 San Diego California 92123
Solutions Through Adv Rch /ID# 226104 Jacksonville Florida 32256
Olympian Clinical Research- St. Petersburg /ID# 226106 St. Petersburg Florida 33709-1405
Advanced Clinical Research Institute /ID# 248827 Tampa Florida 33607
University Dermatology and Vein Clinic, LLC /ID# 226100 Darien Illinois 60561
Arlington Dermatology /ID# 226097 Rolling Meadows Illinois 60008
Skin Cancer and Dermatology Institute - Reno /ID# 248828 Reno Nevada 89509
Univ Hosp Cleveland /ID# 248825 Cleveland Ohio 44106
Apex Clinical Research Center /ID# 248830 Mayfield Heights Ohio 44124
Medical University of South Carolina /ID# 248831 Charleston South Carolina 29425
West Virginia University Hospitals /ID# 263438 Morgantown West Virginia 26506
Wisconsin Medical Center /ID# 263437 Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04862286, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2025 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04862286 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →